Impact of SOX10 on the Proliferation, Invasion, Migration, and EMT in TNBC

Overview

This study investigates the role of SOX10 in promoting proliferation, migration, and invasion in triple-negative breast cancer (TNBC) cells. It highlights the activation of the Wnt/β-catenin signaling pathway and its implications for epithelial-mesenchymal transition (EMT) in TNBC.

Background

Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited treatment options, making it a significant clinical challenge. The understanding of molecular mechanisms driving TNBC progression is crucial for developing targeted therapies. SOX10 has been implicated in tumor progression across various malignancies, but its specific role in TNBC requires further exploration.

Data Highlights

Key Findings

• SOX10 overexpression promotes TNBC cell proliferation, migration, and invasion.
• SOX10 knockdown significantly inhibits these malignant behaviors.
• SOX10 enhances the expression of mesenchymal markers and Wnt/β-catenin pathway components.
• Activation of the Wnt pathway reverses EMT suppression caused by SOX10 knockdown.
• Inhibition of the Wnt pathway mitigates the EMT promotion induced by SOX10 overexpression.

Clinical Implications

Targeting the SOX10-Wnt/β-catenin signaling axis may provide a novel therapeutic strategy for TNBC. Understanding the role of SOX10 in EMT could inform treatment approaches aimed at reducing metastasis and improving patient outcomes.

Conclusion

The findings underscore the importance of SOX10 in TNBC progression through its role in EMT and Wnt signaling. Further research is warranted to explore therapeutic interventions targeting this pathway.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Blood Cancer Journal — Elevated SOX2 Levels Correlate with Decreased Survival Rates in Newly Diagnosed Multiple Myeloma Patients
3. The ASCO Post — Extracellular Matrix Stiffness Promotes Malignant Progression Via PTEN-Reducing Effect of Micro-RNA
4. Frontiers in Oncology — Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
5. Frontiers in Oncology — Novel insights into triple-negative breast cancer heterogeneity, prognosis, and treatment response based on matrix stiffness: a combined single-Cell and transcriptome analysis
6. Early-stage immuno prolongs OS in triple-negative breast cancer
7. Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer | Cancer Research | American Association for Cancer Research
8. The diagnostic significance of immunohistochemical expression of SOX10 and TRPS1 in triple negative breast cancer - ScienceDirect